Opening the door to universal proteomics

The genomic revolution has had a dramatic impact on science and healthcare, but an individual’s genome is just a small part of their being — a biological parts catalogue describing propensity but not current status. Proteins are the structural and functional units of biology.

Unravelling and quantifying the proteome - the full collection of protein abundance, interactions, post-translational modifications, protein misfolding, and accumulated damage - will cause a paradigm shift in biology and medicine, transforming how we live our lives and manage disease.

scientist looking through magnifying glass in a lab
scientist looking through magnifying glass in a lab
scientist looking through magnifying glass in a lab
scientist looking through magnifying glass in a lab

Proteins are the structural and functional units of biology

To understand proteins and metabolites is to understand ourselves: how we work, our health, how we respond to treatments and interventions.

Portal’s mission is to provide scientists and clinicians with the tools they need to kick-start the proteomics revolution, enable new discoveries in the fields of health and biology, and reduce the time taken to bring new drugs and treatments to clinical trial.

3 people in a lab with one writing on a whiteboard
3 people in a lab with one writing on a whiteboard
3 people in a lab with one writing on a whiteboard
3 people in a lab with one writing on a whiteboard
person in lab working on laptop
person in lab working on laptop
person in lab working on laptop

Unprecedented resolution delivers valuable insights

Nanopores are nature’s biosensor — devices with exquisite sensitivity, honed over billions of years of evolution. Our products build upon the remarkable properties of biological nanopores, augmented using our deep-expertise in bioengineering, microelectronics, and machine learning, to provide insight on a single-molecule basis.

Our unique approach characterises individual proteins at amino acid resolution, the ability to determine single-point mutations, and the identification and quantification of post-translational modifications (PTMs) without lengthy and cumbersome sample-enrichment procedures.    

Next generation design & manufacture

Next generation design
& manufacture

Next generation design
& manufacture

Portal’s sensitive and massively-parallel technology enables applications where users desire high resolution protein sequencing, high accuracy, rapid sample analysis and throughput combined with simplicity.

Our advances in design and manufacture allow an unmatched cost-of-analysis, making bench-top proteomics a universal reality.

infographic with nanopores at the centre and around it ai deep learning, bioengineering, microelectronics, leading to digitization of biomarkers
infographic with nanopores at the centre and around it ai deep learning, bioengineering, microelectronics, leading to digitization of biomarkers
infographic with nanopores at the centre and around it ai deep learning, bioengineering, microelectronics, leading to digitization of biomarkers
infographic with nanopores at the centre and around it ai deep learning, bioengineering, microelectronics, leading to digitization of biomarkers
infographic with nanopores at the centre and around it ai deep learning, bioengineering, microelectronics, leading to digitization of biomarkers

Team

Team

Team

Team

Portal's category-defining technology would not be possible without the incredible talent of our scientists, engineers and technicians. Supporting them is Portal's executive team, who have over 50 years' combined experience in biosensors and nanopore science.

Andrew Heron

Andrew Heron

CEO & Co-founder

Andy was previously a senior member of the Oxford Nanopore Technology team that was responsible for commercialising its range of gene sequencers. Andy has made significant contributions to the field of nanopore technology in the last 15 years with over 40 patents and multiple publications and brings this knowledge and experience to bear in accelerating Portal’s new products pipeline. Andy completed post-doc work at the Department of Chemistry, Oxford University and has a PhD in chemical biology from Imperial College, London.

Andrew Heron

Andrew Heron

CEO & Co-founder

Andy was previously a senior member of the Oxford Nanopore Technology team that was responsible for commercialising its range of gene sequencers. Andy has made significant contributions to the field of nanopore technology in the last 15 years with over 40 patents and multiple publications and brings this knowledge and experience to bear in accelerating Portal’s new products pipeline. Andy completed post-doc work at the Department of Chemistry, Oxford University and has a PhD in chemical biology from Imperial College, London.

Andrew Heron

Andrew Heron

CEO & Co-founder

Andy was previously a senior member of the Oxford Nanopore Technology team that was responsible for commercialising its range of gene sequencers. Andy has made significant contributions to the field of nanopore technology in the last 15 years with over 40 patents and multiple publications and brings this knowledge and experience to bear in accelerating Portal’s new products pipeline. Andy completed post-doc work at the Department of Chemistry, Oxford University and has a PhD in chemical biology from Imperial College, London.

Giovanni Maglia

Giovanni Maglia

CSO & Co-founder

Giovanni is Professor of Chemical Biology at Groningen University and has been involved in bioengineering applications using nanopores for almost two decades. He has published extensively in the fields of nanopore bioengineering, specifically in relation to proteomics and metabolomics where he has been credited in the design of artificial transmembrane machines. Giovanni holds a PhD from the University of Birmingham, and has completed postdoctoral work at Oxford University in nanopore sequencing.

Giovanni Maglia

Giovanni Maglia

CSO & Co-founder

Giovanni is Professor of Chemical Biology at Groningen University and has been involved in bioengineering applications using nanopores for almost two decades. He has published extensively in the fields of nanopore bioengineering, specifically in relation to proteomics and metabolomics where he has been credited in the design of artificial transmembrane machines. Giovanni holds a PhD from the University of Birmingham, and has completed postdoctoral work at Oxford University in nanopore sequencing.

Giovanni Maglia

Giovanni Maglia

CSO & Co-founder

Giovanni is Professor of Chemical Biology at Groningen University and has been involved in bioengineering applications using nanopores for almost two decades. He has published extensively in the fields of nanopore bioengineering, specifically in relation to proteomics and metabolomics where he has been credited in the design of artificial transmembrane machines. Giovanni holds a PhD from the University of Birmingham, and has completed postdoctoral work at Oxford University in nanopore sequencing.

Selly Saini

Selly Saini

COO

Selly has held senior positions in the medical devices and diagnostics sectors for over twenty years, and has brought multiple products into healthcare markets. He was previously VP at Johnson & Johnson, CEO at Inside Biometrics, Senior Director of Operations at Oxford Nanopore and COO at Quanta Dialysis Technologies. Selly has broad experience and specialises in scaling companies, operating in regulated markets, gaining reimbursement with first-in-class products through clinical studies and developing robust, high-volume manufacturing supply chains. Selly has a PhD in bioelectronics from Cranfield University and performed post-doc work at the Swiss Federal Institute of Technology (ETH-Z).

Selly Saini

Selly Saini

COO

Selly has held senior positions in the medical devices and diagnostics sectors for over twenty years, and has brought multiple products into healthcare markets. He was previously VP at Johnson & Johnson, CEO at Inside Biometrics, Senior Director of Operations at Oxford Nanopore and COO at Quanta Dialysis Technologies. Selly has broad experience and specialises in scaling companies, operating in regulated markets, gaining reimbursement with first-in-class products through clinical studies and developing robust, high-volume manufacturing supply chains. Selly has a PhD in bioelectronics from Cranfield University and performed post-doc work at the Swiss Federal Institute of Technology (ETH-Z).

Selly Saini

Selly Saini

COO

Selly has held senior positions in the medical devices and diagnostics sectors for over twenty years, and has brought multiple products into healthcare markets. He was previously VP at Johnson & Johnson, CEO at Inside Biometrics, Senior Director of Operations at Oxford Nanopore and COO at Quanta Dialysis Technologies. Selly has broad experience and specialises in scaling companies, operating in regulated markets, gaining reimbursement with first-in-class products through clinical studies and developing robust, high-volume manufacturing supply chains. Selly has a PhD in bioelectronics from Cranfield University and performed post-doc work at the Swiss Federal Institute of Technology (ETH-Z).

Tim Massinfham

Tim Massingham

VP ML & Bioinformatics

Tim has been involved in the fields of machine learning and bioinformatics for over twenty years. He led the machine learning work at Oxford Nanopore for several years, driving fundamental changes in the algorithms that in turn created valuable improvements to sequencing performance. Prior to this he spent ten years as a staff scientist at the EMBL - European Bioinformatics Institute, where he researched bioinformatics algorithms. Tim has a PhD in Computational Biology from Cambridge University where he also completed Master’s and Bachelor's degrees in Mathematics.

Tim Massinfham

Tim Massingham

VP ML & Bioinformatics

Tim has been involved in the fields of machine learning and bioinformatics for over twenty years. He led the machine learning work at Oxford Nanopore for several years, driving fundamental changes in the algorithms that in turn created valuable improvements to sequencing performance. Prior to this he spent ten years as a staff scientist at the EMBL - European Bioinformatics Institute, where he researched bioinformatics algorithms. Tim has a PhD in Computational Biology from Cambridge University where he also completed Master’s and Bachelor's degrees in Mathematics.

Tim Massinfham

Tim Massingham

VP ML & Bioinformatics

Tim has been involved in the fields of machine learning and bioinformatics for over twenty years. He led the machine learning work at Oxford Nanopore for several years, driving fundamental changes in the algorithms that in turn created valuable improvements to sequencing performance. Prior to this he spent ten years as a staff scientist at the EMBL - European Bioinformatics Institute, where he researched bioinformatics algorithms. Tim has a PhD in Computational Biology from Cambridge University where he also completed Master’s and Bachelor's degrees in Mathematics.

Careers

Join our dynamic team at the forefront of proteomics and biotechnology. At Portal Biotech, we are dedicated to revolutionizing the way we understand and manipulate proteins to drive advancements in human health, technology and biology. If you are passionate about cutting-edge science and making a difference, please get in touch.

Contact us

For general enquiries, please email us at info@portalbiotech.com

For careers enquiries, please email us at careers@portalbiotech.com

lab with 5 different people working on different stations
lab with 5 different people working on different stations
lab with 5 different people working on different stations
lab with 5 different people working on different stations